The expression of HER-2 and its prognostic implication in patients with non-small cell lung cancer

李铸鹏; 张丹; 李丹; 苏丹; 应莉莎; 毛伟敏

doi:10.3969/j.issn.1007-3969.2014.09.007

您当前的位置：

首页 >

文章列表页 >

The expression of HER-2 and its prognostic implication in patients with non-small cell lung cancer

更新时间：2025-12-31

- The expression of HER-2 and its prognostic implication in patients with non-small cell lung cancer
- China Oncology Vol. 24, Issue 9, Pages: 679-683(2014)
- 作者机构：
  
  1. 温州医科大学第一临床学院心胸外科系,浙江,温州,325000
  2. 浙江省中医药大学药学院药理系,浙江,杭州,310000
  3. 浙江省中医药大学第一临床肿瘤学系,浙江,杭州,310000
  4. 浙江省肿瘤医院研究所,浙江,杭州,310000
  5. 浙江省肿瘤医院胸外科,浙江,杭州,310000
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2014.09.007
  CLC：
- Published Online：12 November 2014，
  
  Published：12 November 2014
- 稿件说明：
移动端阅览
李铸鹏,张丹,李丹,苏丹,应莉莎,毛伟敏. HER-2在非小细胞肺癌中的表达及与预后的关系[J]. 中国癌症杂志, 2014, 24(9): 679-683.

李铸鹏, 张丹, 李丹, et al. The expression of HER-2 and its prognostic implication in patients with non-small cell lung cancer[J]. China Oncology, 2014, 24(9): 679-683.
李铸鹏,张丹,李丹,苏丹,应莉莎,毛伟敏. HER-2在非小细胞肺癌中的表达及与预后的关系[J]. 中国癌症杂志, 2014, 24(9): 679-683. DOI： 10.3969/j.issn.1007-3969.2014.09.007.

李铸鹏, 张丹, 李丹, et al. The expression of HER-2 and its prognostic implication in patients with non-small cell lung cancer[J]. China Oncology, 2014, 24(9): 679-683. DOI： 10.3969/j.issn.1007-3969.2014.09.007.

摘要

背景与目的：人类表皮生长因子受体2(human epidermal growth factor receptor 2，HER-2)对非小细胞肺癌(non-small cell lung cancer，NSCLC)患者预后的提示作用还处于争议之中，本研究旨在探索HER-2在NSCLC中的表达及与预后的关系。方法：利用免疫组化检测425例NSCLC的HER-2的表达。χ2检验评价HER-2与临床病理参数的关系。COX比例风险回归评估HER-2与预后的关系。结果：在425例组织中，HER-2阳性表达83例(19.5%)；HER-2表达与NSCLC的病理类型密切相关，腺癌中的表达最高(P=0.05)。COX回归显示HER-2与NSCLC的预后无相关性。结论：HER-2表达与NSCLC的病理类型密切相关，在腺癌中表达比较普遍，但与NSCLC的预后无关。

Abstract

Background and purpose: The prognostic role of human epidermal growth factor receptor 2 (HER-2) remains controversial in patients with non-small cell lung cancer (NSCLC). This study aimed to evaluate the expression of HER-2 and its prognostic implication in patients with NSCLC. Methods: Four hundred and twenty-five NSCLC patients’ specimens were obtained from Zhejiang Cancer Hospital. HER-2 protein expression was determined by immunohistochemistry (IHC). The relationship between HER-2 and clinicopathological parameters and patients’ prognosis was analyzed by Chi-square test and COX proportional hazards regression model. Results: Eighty-three patients were positive expression of HER-2 (83/425

19.5%). The expression of HER-2 was closely related with histological type (P=0.051)

most patients with HER-2 positive were adenocarcinoma

then were squamous carcinoma or other histological types. However

HER-2 was not an independent prognostic indicator for the overall survival of patients with NSCLC. Conclusion: We found that the expression of HER-2 was closely connected with histological type

but it was not a predictive marker for the prognosis in patients with NSCLC.

关键词

Keywords

references

Views

1682

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress of immune contexture in tumorigenesis, progression and prognostic relevance of non-small cell lung cancer

Clinical research progress of tumor mutational burden inEGFR-mutant advanced non-small cell lung cancer

The analysis of treatment decision and prognosis of stage Ⅲ non-small cell lung cancer in the multidisciplinary team

NRP1 expression is associated with chemosensitivity and poor prognosis in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy

Correlation between δ-catenin and Cdc42 expression in non-small cell lung cancer

Related Author

申宇嘉

傅小龙

何　夕

焦晓栋

臧远胜

吴　梅

李应龙

单　莉

Related Institution

上海交通大学附属胸科医院放疗科

上海交通大学医学院

海军军医大学附属长征医院肿瘤科

新疆医科大学第三临床医学院肺内科一病区

佛山市第一人民医院头颈胸肿瘤内科

AI问答

⁰